Large language models are helping scientists to converse with artificial intelligence and even to generate potential drug targets.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Leveraging generative AI to prioritize drug repurposing candidates for Alzheimer’s disease with real-world clinical validation
npj Digital Medicine Open Access 26 February 2024
-
ChatGPT and mycosis– a new weapon in the knowledge battlefield
BMC Infectious Diseases Open Access 27 October 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
02 May 2023
In the version of this article initially published, Andrew Beam’s roles were incorrectly described and have now been updated.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Savage, N. Drug discovery companies are customizing ChatGPT: here’s how. Nat Biotechnol 41, 585–586 (2023). https://doi.org/10.1038/s41587-023-01788-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-023-01788-7
This article is cited by
-
Leveraging generative AI to prioritize drug repurposing candidates for Alzheimer’s disease with real-world clinical validation
npj Digital Medicine (2024)
-
Characterizing emerging companies in computational drug development
Nature Computational Science (2024)
-
Advancing the Production of Clinical Medical Devices Through ChatGPT
Annals of Biomedical Engineering (2024)
-
Innovating Healthcare: The Role of ChatGPT in Streamlining Hospital Workflow in the Future
Annals of Biomedical Engineering (2024)
-
ChatGPT and mycosis– a new weapon in the knowledge battlefield
BMC Infectious Diseases (2023)